Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking strategy to diabetes management. These innovative drugs function by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to meals. By triggering GLP-1 receptors in the pancreas, these sub

Retaglutide and tirzepatide represent a novel class of medications known as dual GLP-1 and GIP agonists. These agents target both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that play a crucial role in regulating blood sugar levels. In i